Prostatic Hyperplasia (Benign Prostatic Hyperplasia)

Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.

Also Known As:

Networked: 6562 relevant articles (591 outcomes, 1080 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer)
2.	Urinary Retention
3.	Overactive Urinary Bladder (Overactive Bladder)
4.	Urinary Bladder Neck Obstruction (Bladder Neck Obstruction)
5.	Nocturia

Experts

1.	Kaplan, Steven A: 91 articles (01/2016 - 10/2002)
2.	Roehrborn, Claus G: 74 articles (09/2015 - 06/2002)
3.	Viktrup, Lars: 29 articles (10/2015 - 10/2008)
4.	McVary, Kevin T: 27 articles (09/2015 - 05/2003)
5.	Montorsi, Francesco: 26 articles (10/2015 - 03/2004)
6.	Te, Alexis E: 20 articles (01/2016 - 06/2002)
7.	Roehrborn, C G: 20 articles (03/2015 - 01/2000)
8.	Elhilali, Mostafa M: 18 articles (10/2015 - 10/2005)
9.	Maggi, Mario: 18 articles (11/2013 - 01/2006)
10.	Masumori, Naoya: 17 articles (06/2015 - 06/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Prostatic Hyperplasia:

1.	tamsulosin (Flomax)FDA LinkGeneric 01/01/2013 - "Tamsulosin hydrochloride is one of the most potent drugs for treatment of benign prostatic hyperplasia (BPH), however, the efficacy of tamsulosin hydrochloride varies among individuals. " 07/01/2013 - "Tamsulosin HCl capsules showed a significant statistical improvement in the erectile function, sexual desire, and intercourse satisfaction score with significant improvement in total IIEF in patients with lower urinary tract symptoms because of benign prostatic hyperplasia." 11/01/2012 - "Combination therapy significantly increased the time to benign prostatic hyperplasia clinical progression and resulted in improved International Prostate Symptom Score, maximum urinary flow rate, quality of life, and reduced prostate volume in Asian and Caucasian men who received combination therapy compared with tamsulosin monotherapy. " 06/24/2009 - "Tamsulosin (0.3-300 microg/kg) also dose-dependently inhibited the intraurethral pressure increase in both groups, but it had a hypotensive effect that was significantly greater in old than in young dogs with benign prostatic hyperplasia. " 11/01/1998 - "Tamsulosin was safe and effective, and clinically and statistically superior to placebo in relieving symptoms of benign prostatic hyperplasia in men with moderate to severe symptoms at baseline. "
2.	Finasteride (Propecia)FDA LinkGeneric 11/01/2007 - "One hundred twenty patients with a clinical diagnosis of benign prostatic hyperplasia (BPH), sexually active and with an International Index of Erectile Function-erectile function (IIEF-EF) domain >/=25 were randomized to receive finasteride 5 mg concealed as an "X compound of proven efficacy for the treatment of BPH" for 1 year with (group 2) or without (group 1) counseling on the drug sexual side effect. " 05/01/2009 - "A significantly greater proportion of patients using multiple medications and finasteride were adherent with any benign prostatic hyperplasia medication (62% and 55%, respectively, p <0.0001). " 01/01/1995 - "The total, obstructive and non-obstructive symptom scores decreased (improved) for patients on 1 and 5 mg finasteride, with the total score reducing by 33% from baseline at year 3. The results demonstrate that finasteride causes a modest but significant clinical improvement in men with urinary outflow obstruction secondary to benign prostatic hyperplasia." 04/01/2008 - "Two landmark multi-centre trials, MTOPS and PCPT, have shown that finasteride is an effective treatment of micturitional disorders due to benign prostatic hyperplasia, reducing the clinical progression of BPH. " 07/24/2009 - "Finasteride is a mechanism-based inactivator of 5alpha-reductase type 2 with subnanomolar affinity and is widely used as a therapeutic for the treatment of benign prostatic hyperplasia. "
3.	Doxazosin (Cardura)FDA LinkGeneric 06/10/2005 - "These findings, that demonstrate chronic doxazosin administration causes significant changes in the expression of several hundred genes in the rat prostate, may provide insight into the long-term efficacy of alpha1-AR antagonists in the treatment of benign prostatic hyperplasia." 01/01/2015 - "To compare the efficacy of 4 mg and 8 mg doxazosin XL treatments in patients with benign prostatic hyperplasia-related lower urinary tract symptoms and determine the efficiency of 8 mg in those patients with inadequate response to 4 mg. A total of 162 patients were included in this study. " 09/01/1996 - "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." 03/01/1994 - "In a placebo-controlled study, the safety and efficacy of the selective alpha 1-adrenoceptor-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia (BPH) were evaluated. " 01/01/1993 - "The safety and efficacy of the selective alpha 1-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia were evaluated in a randomized, double-blind and placebo-controlled 9-week study of 100 patients. "
4.	alfuzosin (UroXatral)FDA Link 12/01/2001 - "The results of 2 double-blind, placebo-controlled phase 3 studies in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia suggests that 10 mg of alfuzosin administered once daily without dose titration is superior to placebo in terms of symptom and urinary flow rate improvement. " 02/01/2013 - "The purpose of present research was to develop and optimize sustained release floating pellets of alfuzosin hydrochloride which has narrow absorption window in proximal intestine to improve patient compliance and therapeutic efficacy in the treatment of benign prostatic hyperplasia. " 04/01/2000 - "Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice." 01/01/2002 - "To evaluate the long-term safety and efficacy of a new, once-daily (o.d.) prolonged-release formulation of the clinically uroselective alpha1-blocker, alfuzosin, in patients with symptomatic benign prostatic hyperplasia (BPH). " 12/01/2001 - "Alfuzosin 10 mg OD, administered without dose titration, provides effective relief from the symptoms of benign prostatic hyperplasia with no additional benefit from a 15-mg dose. "
5.	dutasteride (Avodart)FDA Link 03/01/2014 - "Dutasteride is highly effective in mitigating benign prostatic hyperplasia symptoms and reducing the size of enlarged prostate and the risks of AUR and surgical intervention. " 01/01/2013 - "Dutasteride significantly decreased the incidence of benign prostatic hyperplasia clinical progression." 11/01/2012 - "Combination therapy also significantly improved (P < 0.05) time to benign prostatic hyperplasia clinical progression, International Prostate Symptom Score, maximum urinary flow rate and quality of life versus dutasteride in the Caucasian subpopulation. " 09/01/2005 - "Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies." 08/01/2014 - "Dutasteride is effective in relieving lower urinary tract symptoms by improving storage and voiding function, as well as subjective symptoms in patients with benign prostatic hyperplasia."
6.	tadalafil (Cialis)FDA Link 01/01/2014 - "In dose-ranging and confirmatory studies, results demonstrate that tadalafil significantly improved total International Prostate Symptom Score (IPSS) following 12 weeks of treatment with once daily tadalafil 5 mg. Statistically significant improvements in Benign Prostatic Hyperplasia Impact Index (BII), IPSS subscores, IPSS QOL and International Index of Erectile Function (IIEF) were also observed. " 01/01/2015 - "A significant percentage of patients with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) achieve clinically meaningful improvement when receiving placebo or tadalafil 5mg once daily. " 05/01/2015 - "Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies." 05/01/2015 - "Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia – integrated data from 1,499 study participants." 05/01/2015 - "Of 234 category 1 responders with week 1 assessments 140 (59.8%) achieved clinically meaningful improvement by week 1 and 407 of the total of 513 category 1 responders (79.3%) showed it by week 4. Of the 205 category 2 responders with week 1 assessments 103 (50.2%) achieved clinically meaningful improvement by week 1 while 322 of the 444 category 2 responders (72.5%) did so by week 4. Tadalafil 5 mg once daily led to clinically meaningful improvement in approximately two-thirds of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. "
7.	Terazosin (Hytrin)FDA LinkGeneric 12/01/1988 - "The results at four months of a six-month study support the conclusion that terazosin is beneficial for treatment of symptoms in patients with benign prostatic hypertrophy." 10/01/1989 - "These preliminary results confirm that terazosin significantly improved peak as well as mean urine flow rates and significantly reduced residual volume and significantly improved obstructive symptoms in patients with benign prostatic hyperplasia (p less than 0.001). " 11/01/2007 - "The analysis of case histories of 41 patients after open TVPE for prostatic adenoma has shown that setegis (terazosin) is effective in therapy of urinary bladder overactivity which is present in the majority of patients after TVAE. " 01/01/1992 - "Terazosin was found to be safe and effective in the dose range of 2-20 mg taken at bedtime in men with symptoms related to benign prostatic hyperplasia. " 03/01/1996 - "This study was designed to evaluate the safety and efficacy of the selective alpha 1-adrenoceptor blocker terazosin in the treatment of benign prostatic hyperplasia (BPH). "
8.	naftopidilIBA 01/01/2002 - "Naftopidil tablet was safe and effective in treating benign prostatic hyperplasia." 09/01/2011 - "The present study investigated the early efficacy of naftopidil against lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). " 07/01/2004 - "The aim of our study was to examine the efficacy of naftopidil in terms of the international prostate symptom score (IPSS) and urodynamic parameters in the treatment of benign prostatic hyperplasia (BPH). " 05/01/2013 - "Editorial comment from Dr Funahashi to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy." 05/01/2013 - "To examine the efficacy of dose increase therapy in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia who responded poorly to 50 mg/day of naftopidil. "
9.	Prostate-Specific Antigen (Semenogelase)IBA 06/01/2013 - "To investigate the efficacy of total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) for the estimation of prostate volume (PV) in pathologically-proven benign prostatic hyperplasia (BPH) patients. " 08/01/2001 - "From these results, it is evident that Prostane was effective in alleviating symptoms, reducing prostate specific antigen values and normalizing uroflow dynamics in patients with benign prostatic hypertrophy." 12/01/2008 - "It improved patient prostate specific antigen, American Urological Association symptom score and maximum urinary flow rate independent of the amount of benign prostatic hyperplasia present. " 12/01/1995 - "The AUA symptom scores improved on average by 6.3 points; prostatic adenoma volume reduced from baseline by 17%, and the serum prostate specific antigen (PSA) level decreased by 35%. " 12/01/2009 - "This study investigated relationships between total prostate-specific antigen (tPSA), free prostate-specific antigen (fPSA), and prostate volume (PV) in Chinese men with biopsy-proven BPH, and analyzed whether fPSA performed better than tPSA at estimating thresholds of PV. From 2003 to 2008, a total of 286 patients with a PSA less than 10 ng/ml and biopsy proven benign prostatic hyperplasia were included in this study. "
10.	KMD 3213FDA Link 01/01/2013 - "Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies." 06/01/2009 - "Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies." 05/07/2011 - "In men aged >50 years with benign prostatic hyperplasia (BPH), silodosin 8 mg once daily, compared with placebo, was associated with a significantly more rapid and effective improvement in the total International Prostate Symptom Score (IPSS) and the storage and voiding IPSS subscores in three 12-week, phase III trials conducted in Europe and the US. " 01/01/2011 - "The uroselective α-blocker silodosin significantly improved International Prostate Symptom Score (IPSS) in two 12-week, double-blind (DB), placebo-controlled Phase III studies in men aged ≥ 50 years with symptoms of benign prostatic hyperplasia (BPH) and maintained symptom improvement during a 9-month open-label (OL) extension. " 01/01/2010 - "Pooled results from 2 randomized, placebo-controlled, US phase III studies (NCT00224107, NCT00224120) showed that silodosin, a uroselective α-blocker, significantly improved International Prostate Symptom Scores (IPSS) in men with symptomatic benign prostatic hyperplasia (BPH). "

Therapies and Procedures

1.	Transurethral Resection of Prostate (TURP) 02/01/2013 - "Transurethral resection of the prostate (TURP) is the most common surgical procedure in urology and remains the gold standard treatment of complicated benign prostatic hyperplasia or refractory to medical treatment. " 05/01/1993 - "Transurethral resection of the prostate (TURP) is the most effective treatment for prostatic obstruction secondary to benign prostatic hyperplasia (BPH). " 09/03/1997 - "[Transurethral thermotherapy of the prostate--a very promising treatment method for benign prostatic hyperplasia]." 01/01/2012 - "Transurethral resection of the prostate (TURP) has long been held as the gold standard for treatment of benign prostatic hyperplasia (BPH); however, there has been significant innovation in other less invasive alternative treatments for BPH in recent years. " 11/01/2007 - "Despite the fact that transurethral resection of the prostate (TURP) continues being the gold standard for the surgical treatment of benign prostatic hyperplasia (BPH), the good results obtained with the use of new energy sources have led to their use in daily practice. "
2.	Lasers (Laser) 01/01/2015 - "Photoselective vaporization of the prostate (PVP) using the new 180-W XPS GreenLight laser system seems to be a safe and effective procedure and could play an important role in the surgical treatment of symptomatic benign prostatic hyperplasia (BPH) patients with larger prostate volumes." 01/01/2013 - "The use of lasers to perform photoselective vaporization of the prostate (PVP) has been widely accepted as a safe and effective treatment for benign prostatic hyperplasia with very few reported complications. " 04/01/2011 - "With the use of 12 months of follow-up data, this study was conducted to evaluate the efficacy of photoselective vaporization of the prostate (PVP) with the 120 W Greenlight high performance system (HPS) laser for the treatment of symptomatic benign prostatic hyperplasia. " 05/01/2015 - "Efficacy of a vaporization-resection of the prostate median lobe enlargement and vaporization of the prostate lateral lobe for benign prostatic hyperplasia using a 120-W GreenLight high-performance system laser: the effect on storage symptoms." 07/01/2011 - "To evaluate the safety and efficacy of 120-W high-performance system (HPS) laser photoselective vaporization of the prostate (PVP) in the treatment of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. "
3.	Solid-State Lasers 08/01/2010 - "Holmium laser enucleation of the prostate is highly effective for symptomatic benign prostatic hyperplasia. " 09/01/2008 - "Holmium laser enucleation of the prostate is the single best treatment for benign prostatic hyperplasia refractory to medication." 01/01/2011 - "Holmium laser enucleation of the prostate is superior to other modalities for the treatment of benign prostatic hyperplasia. " 01/01/2006 - "More recently, higher power potassium-titanyl-phosphate lasers have been introduced and show promise for the treatment of benign prostatic hyperplasia. " 12/01/2008 - "Randomized, controlled trials have demonstrated that holmium laser enucleation of the prostate is a viable and effective treatment for benign prostatic hyperplasia. "
4.	Prostatectomy (Retropubic Prostatectomy) 01/01/1997 - "Free and complexed PSA have different clearances and significant differences between clearance of free PSA after radical prostatectomy (RP) and after open surgery for benign prostatic hyperplasia (BPH) are observed. " 10/01/1990 - "Whilst prostatectomy remains the "gold standard" for the treatment of outflow tract obstruction due to benign prostatic hyperplasia, medical treatment--if only for symptomatic relief--appears to be an attractive alternative. " 02/01/2002 - "Suprapubic transvesical prostatectomy, performed under spinal anaesthetic, by general surgeons in rural Kenya, is a safe and effective way of managing benign prostatic hyperplasia and its complications." 04/01/2014 - "To compare the safety and efficacy of transurethral plasmakinetic resection of the prostate (PKRP) versus transvesical prostatectomy (TVP) in the treatment of large-volume benign prostatic hyperplasia (LV-BPH) (100-149 mL). " 07/01/2001 - "A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia."
5.	Laser Therapy (Surgery, Laser) 09/30/2014 - "Laser vaporization of the prostate is considered to be a promising treatment for benign prostatic hyperplasia (BPH), and efficiency of vaporization and hemostasis are both important parameters for such treatment. " 07/01/2013 - "[Efficacy of a high-power laser vaporization in comparison with a monopolar transurethral resection in the treatment of benign prostatic hyperplasia: results of a 6-months follow-up]." 04/01/1997 - "Benign prostatic hyperplasia--which tests predict good outcomes following transurethral resection of the prostate and the role of laser vaporization in treatment." 06/01/1995 - "Endoscopic laser ablation is a new treatment for benign prostatic hypertrophy. " 10/01/2012 - "The aim of this study was to compare the efficacy of GreenLight 120W-HPS (American Medical Systems, Minnetonka, Minnesota, USA) laser vaporization for men with obstructive benign prostatic hyperplasia (BPH) according to prostate volumes < 60 cc, 60 cc-100 cc and > 100 cc. "